Article
The Value of Tissue Protein Expression as a Predictor of Efficacy for First- or Second-line Therapy (tx) in Metastatic Ductal Pancreas Cancer (PDAC) in Patients (pts) Receiving either Gemcitabine (G)-based tx or 5FU (F)-based tx.
Journal of Clinical Oncology
(2015)
Disciplines
Publication Date
January 20, 2015
DOI
10.1200/jco.2015.33.3_suppl.460
Citation Information
Lauren Carcas, Jessica Macintyre, Jaime R. Merchan, Peter Joel Hosein, et al.. "The Value of Tissue Protein Expression as a Predictor of Efficacy for First- or Second-line Therapy (tx) in Metastatic Ductal Pancreas Cancer (PDAC) in Patients (pts) Receiving either Gemcitabine (G)-based tx or 5FU (F)-based tx." Journal of Clinical Oncology Vol. 33 (2015) p. 460 - 460 Available at: http://works.bepress.com/lauren-carcas/3/